When the microbiome helps the brain-current evidence

CNS Neurosci Ther. 2023 Jun;29 Suppl 1(Suppl 1):43-58. doi: 10.1111/cns.14076. Epub 2023 Jan 4.

Abstract

The gut microbiota-brain axis has been recognized as a network of connections that provides communication between the gut microflora and both central and autonomic nervous system. The gut microbiota alteration has been targeted for therapy in various neurodegenerative and psychiatric disbalances. Psychobiotics are probiotics that contribute beneficially to the brain function and the host mental health as a result of an interaction with the commensal gut bacteria, although their mechanism of action has not been completely revealed. In this state-of-art review, the findings about the potential therapeutic effects of the psychobiotics alone or in combination with conventional medicine in the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as well as in some psychiatric diseases like depression, schizophrenia, and bipolar disorder, have been summarized. The evidence of the psychobiotics therapeutic outcomes obtained in preclinical and clinical trials have been given respectively for the observed neurodegenerative and psychiatric disorders.

Keywords: alzheimer disease; gut microbiota; parkinson disease; psychiatric disease; psychobiotics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain
  • Gastrointestinal Microbiome* / physiology
  • Humans
  • Microbiota* / physiology
  • Neurodegenerative Diseases* / therapy
  • Parkinson Disease*